Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.
Full-Life Technologies is a radiotherapeutics company that provides research and development, production, and commercialization of radiopharmaceuticals for cancer therapy, delivering clinical impact for patients.
Grit Science is a gene therapeutics firm, that engages in the R&D of liver genes.
ABclonal Technology is a rapidly growing life science research and diagnostic reagents provider. With scientists from world-class universities, the company thrives on improving the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS library preparation kits and molecular enzymes.
Duoning Biotech is a serum-free medium and technology developer based on international animal cell culture concepts and process development experience. It is committed to the development and production of serum-free media for new animal cells, while providing formula production and technical support for the biopharmaceutical industry. With ancillary services, the products include basic media such as S1, S2, S3, S3-CD and S4, as well as 2×103 feeds and other feed media based on 2×103 feeds; and customized services.
Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.
Bota Biosciences (Bota Bio) is a global industrial biotechnology company connecting biological design to scale-up manufacturing to accelerate shifts to sustainable living. Bota has built an integrative bioengineering platform, to develop and implement efficient, eco-friendly, and cost-effective biomanufacturing technologies. Committed to its mission, Bota established its own pilot plant and manufacturing facility, affirming its dedication to offering scalable industrial solutions and market-ready products. This infrastructure strengthens support for customers and partners across industries such as nutrition, food, personal care, and animal health. Powered by a dynamic, multidisciplinary team, Bota Bio channels biotech innovations to create a global impact. The company's Series B financing has surpassed $100 million, bringing its aggregate funding to $145 million, with investment from notable strategic and financial investors, including Hong Shan Capital, Matrix Partners, and BASF Ventures.
Biosysen is a synthetic biology company specializing in software-based species design and biomanufacturing. The company utilizes software engineering principles to enhance the self-replication and scalability of biological systems, aiming to unlock the full productivity potential of the biological industry. Biosysen's primary offerings include a library of artificial species and related industrial pipelines tailored for specific applications. These products cater to various sectors, including food production, medical testing, daily chemicals, and protein drug development, thereby supporting innovation and efficiency in these industries.
HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.
Analytical Biosciences is a single-cell genome developer that aims to create and apply accurate maps of human diseases. In collaboration with medical research institutions, hospitals, and pharmaceutical companies, we are committed to exploiting the application of single-cell genomics and bioinformatics in the diagnosis and treatment of human diseases. Through large-scale systematic disease single-cell mapping, big data intelligence mining is carried out to help a wide range of partners discover new therapeutic targets and develop new treatment strategies.
Benchling is the modern software platform purpose-built for life science R&D. Hundreds of thousands of scientists using cutting-edge techniques like CRISPR, CAR-T immunotherapy, and genetic engineering depend on our suite of cloud applications to design DNA, collaborate on experiments, manage research workflows, and make critical R&D decisions.
ABclonal Technology is a rapidly growing life science research and diagnostic reagents provider. With scientists from world-class universities, the company thrives on improving the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS library preparation kits and molecular enzymes.
Jifan Biotechnology is a biotechnology firm that provides molecular biology reagents, diagnostic raw materials, and kits for research.
VISEN is an innovative biopharmaceutical company focused on endocrine diseases. We are dedicated to providing innovative therapies and compassionate, patient-centric care, because we believe that achieving better treatment processes and outcomes results in living better lives. Putting patients’ need first, VISEN is committed to providing first-in-class or best-in-class products and treatments for endocrine diseases. Our therapeutic areas cover endocrine diseases in adults and children, and rare endocrine diseases. VISEN comprises seasoned professionals with multinational pharmaceutical experiences and leverages cutting-edge technologies and leading resources across the world. We are focused on the Chinese market, and have established offices in Shanghai, Beijing, Hong Kong and Taipei. We have also launched our Greater China R&D and manufacturing site in Suzhou to enhance R&D, manufacturing and commercialization efforts. Our goal is to enable Chinese endocrine patients to benefit from the world's most advanced and reliable treatment solutions earlier.
Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.
SciNeuro Pharmaceuticals is a biotechnology company based in Shanghai, China, focused on developing innovative medicines for patients with central nervous system (CNS) diseases. The company is committed to transforming the treatment landscape for these conditions through a robust product pipeline that emphasizes internal innovation and global collaboration. SciNeuro's drug development is guided by breakthrough scientific evidence, including insights from human genetics and pharmacology, targeting the underlying mechanisms of CNS diseases. By addressing these pathological mechanisms, SciNeuro aims to provide transformative therapies that not only aim to cure these diseases but also enhance the quality of life for patients.
D3 Bio is a biotechnology company that focuses on discovering and creating medications in oncology and immunology. The company combines clinical and market data to identify shortcomings in existing conventional medicines, employs unique drug development methodologies aimed at new disease targets and delivery routes, and provides patients with therapy alternatives in immunology and oncology.
HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.
Eden Biologics, formerly known as JHL Biotech ("JHL") , is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biologics, from cell line development to commercial manufacturing with both global and regional regulatory affairs expertise.
Brii Biosciences Limited is a biotechnology company focused on the research, development, and commercialization of medicines for chronic illnesses, particularly infectious diseases, liver, and lung conditions. Founded in 2018, the company operates from Durham, North Carolina, with additional offices in Shanghai, Beijing, and San Francisco. Brii Biosciences aims to provide innovative biopharmaceutical solutions tailored to the needs of Chinese patients, addressing public health challenges such as hepatitis B, HIV, and multidrug-resistant infections. The company leverages technology and data to enhance the Chinese healthcare system, ensuring better access to effective treatments. With a diverse pipeline of over ten product candidates, Brii Biosciences is committed to improving health outcomes for patients suffering from both infectious and central nervous system diseases.
HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.
MabSpace Biosciences is a biotechnology company founded in 2013, dedicated to the discovery and development of innovative antibody-based therapeutics for the treatment of cancer and fibrotic diseases affecting organs such as the lungs, kidneys, and liver. Located in Biobay Suzhou, China, an emerging biotech incubator, MabSpace employs its proprietary immune tolerance breaking technology (IMBT) to generate lead antibodies with diverse epitopes that target various components of the tumor microenvironment. This technology has facilitated the establishment of multiple antibody discovery and co-development partnerships. MabSpace's lead antibody program includes a potentially best-in-class anti-PD-L1 antibody characterized by unique pH-dependent binding and recycling properties, which has demonstrated significantly improved efficacy in animal models. Additionally, the company has developed a panel of second-generation immuno-oncology antibodies that support the testing of combination therapeutic interventions alongside its PD-L1 antibody, aiming to enhance treatment outcomes for patients.
MedGenome is a developer of sequencing genomics-based diagnostics and research platform intended to improve global health. The company's platform applies genomics technologies, bioinformatics, computing, and big data analytics to the genetically diverse and large population to understand the genetic basis of cancer, metabolic disorders, eye disorders, and other rare diseases, enabling the healthcare industry to develop deep insights into diseases at the genetic and molecular level.
Celon Laboratories Limited engages in developing, manufacturing, and marketing pharmaceutical products in the areas of oncology, anti-infective, and critical care markets. It produces un-coated and coated tablets, capsules, ampoules, vials, pre-filled syringes, and emulsion injections. The company also provides contract research manufacturing services that include formulation development, lyophilization cycle development, QC testing, stability studies, and regulatory support services. It serves customers in the Asia Pacific, Africa, Latin America, CIS countries, and Eastern Europe. The company was incorporated in 2001 and is based in Hyderabad, India.
MedGenome is a developer of sequencing genomics-based diagnostics and research platform intended to improve global health. The company's platform applies genomics technologies, bioinformatics, computing, and big data analytics to the genetically diverse and large population to understand the genetic basis of cancer, metabolic disorders, eye disorders, and other rare diseases, enabling the healthcare industry to develop deep insights into diseases at the genetic and molecular level.
Celon Laboratories Limited engages in developing, manufacturing, and marketing pharmaceutical products in the areas of oncology, anti-infective, and critical care markets. It produces un-coated and coated tablets, capsules, ampoules, vials, pre-filled syringes, and emulsion injections. The company also provides contract research manufacturing services that include formulation development, lyophilization cycle development, QC testing, stability studies, and regulatory support services. It serves customers in the Asia Pacific, Africa, Latin America, CIS countries, and Eastern Europe. The company was incorporated in 2001 and is based in Hyderabad, India.
SAI is an ideal drug discovery, development and manufacturing partner. Their pharma and biotech clients gain clear competitive advantages through shorter time to market and risk minimization using their integrated and high-quality scientific services. SAI’s mission is to help their partners develop innovative medicines quicker and at lower cost by providing reliable research and manufacturing solutions. Their guiding principles are to be reliable, communicate effectively, safeguard IP, invest in people and to adopt technologies. At SAI Life Sciences, developing a business relationship with their clients that benefits both parties is only the beginning. They have learned through experience, it is when they build a partnership with a customer, that they can truly amplify their mutual interests and successes. At SAI they will call this “+1” and it hints at the additional value they aim to find mutually in longer term relationships.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.